Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benefits of Oxytocin in OSA Patients Using CPAP
NCT03860233Phase 1Recruiting
- Start
- Mar 2019
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of oxytocin nasal spray in obstructive sleep apnea (OSA) (2 arms). Primary endpoint: Change in pressure required to keep open airway during auto-CPAP use at 5 weeks. Started Mar 2019; status: recruiting.
02
Drugs
oxytocin nasal spray
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT03860233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03860233.